Evonile Pharma Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/2dvkqo38vh8uowh671iype30.pdf

Key Takeaways


The Transition: What Broke and What Is Being Built

Vikas Gupta: "Q2 is the quarter in which the old model ended and a new one began. That brings one-time costs, a one-time correction in revenue and upfront investment in people and systems that goes ahead of the revenue. The important point is that these are transition effects. They do not reflect any change in the underlying demand for our brands."

Portfolio Expansion

Vikas Gupta: "We inherited legendary brands with strong prescriber recall, but there was limited focus and investments in these brands. The majority of the sales was through to a single customer. Further distribution and field presence was limited with hardly any promotion on the brands. So demand rested largely on the loyalty that doctors had built up over the years."

Cost Structure and the Path to Stability

Vikas Gupta: "As we said in our September call, our team is sized for the future potential of the portfolio, not for today's pace."

Revenue Runway and Growth Ambition

Vikas Gupta: "We want to move from a stable business to a business that grows above the market. From a portfolio concentrated in a few flagship brands to a broader basket with regular in-licensing acquisitions and new launches. From a single standalone asset to a platform that grows through disciplined M&A. And from cash sitting on the balance sheet to a business focused on growth, ROCE and free cash flow."

Guidance & Commitments

CommitmentSpecificsTimeline
Field force completionAll ~900 MRs on board (including ~300 for Minipress)By end of Q3 or beginning of Q4 FY27
One-time costsAnother ₹15–20 crores in Q3; cost structure stabilized thereafterQ3 FY27; stabilized by Q4 FY27
Stabilized quarterly revenue~₹150 crores per quarterQ4 FY27 or Q1 FY28
FY28 revenueMore than ₹600 croresFY28
Gross margin improvementReal changes from sourcing efficiencies visibleQ1 FY28 onward
New product introductionsBrand extensions and new products for same specialistsLate Q4 FY27 or Q1 FY28
Debt reductionSignificantly reduced via rights issueBy 31 March 2027
Organic growth ambitionDouble the ~₹600 crore stabilized baseOver next 5–6 years

Key Metrics

MetricQ2 FY27
Revenue from operations₹56 cr, compared with ₹90 cr in Q2 FY26, of which ₹41 cr was sales to a major customer
Half-yearly revenue₹160 cr, against ₹178 cr in H1 FY26
Employee costs₹14 cr, up from ₹5 cr in Q2 FY26
Other expenses₹11 cr, almost flat on Q2 FY26 after excluding one-off expenses
Adjusted operating EBITDAnegative ₹16 cr
Half-year adjusted operating EBITDA₹19 cr
Exceptional item₹68 cr, comprising ₹61 cr from termination of exclusive promotion rights and related inventory purchase arrangements with one large customer
One-off expenses (within other expenses)₹15 cr, relating to transition and acquisition-related cost of Minipress XL
Total one-time items₹83 cr
Expected one-time costs in Q3 FY27₹15 cr to ₹20 cr
Stabilized annualized revenue baseclose to around ₹600 cr, post-inheritance and in-licensing of brands
Organic growth targetdouble the base in 5 to 6 years
Target MR strength900, with planned hiring completion by end of Q3 FY27 or early Q4 FY27
Planned MRs for Minipress XL~300 out of the 900
Minipress XL market sharemore than 50%
Minipress XL amortization period20 to 25 years
Expected finance cost Q3 FY27~₹15 cr
Expected finance cost Q4 FY27₹10 cr to ₹15 cr
Stabilized quarterly revenue run-rate indicatoraround ₹150 cr per quarter
FY28 revenue guidancemore than ₹600 cr, growing on a stabilized base of around that number